Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-06 | Lilly Endowment Inc.Société | -15,83k | 15,75M | Vente | 995,23 - 996,18 | 91,88M | -0,02% |
| 2026-02-19 | Mr. Eric DozierExec. VP & CPO | -481,00 | 0,00 | Other Disposition | - | 14,84k | -3,14% |
| 2026-02-16 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | 102,45 | 0,00 | Derivative Exercise and Retained Stock | - | 5,25k | 1,99% |
| 2026-02-16 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -81,55 | 84,82k | Derivative Exercise and Sale | 1,04k | 5,25k | - |
| 2026-02-16 | Mr. Lucas E. MontarceExec. VP & CFO | 208,27 | 0,00 | Derivative Exercise and Retained Stock | - | 16,26k | 1,30% |
| 2026-02-16 | Mr. Lucas E. MontarceExec. VP & CFO | -159,73 | 166,12k | Derivative Exercise and Sale | 1,04k | 16,26k | - |
| 2026-02-16 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | 115,69 | 0,00 | Derivative Exercise and Retained Stock | - | 10,14k | 1,15% |
| 2026-02-16 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | -91,31 | 94,96k | Derivative Exercise and Sale | 1,04k | 10,14k | - |
| 2026-02-16 | Ms. Adrienne BrownExec. VP & President of Lilly Immunology | 221,03 | 0,00 | Derivative Exercise and Retained Stock | - | 5,14k | 4,49% |
| 2026-02-16 | Ms. Adrienne BrownExec. VP & President of Lilly Immunology | -169,97 | 176,76k | Derivative Exercise and Sale | 1,04k | 5,14k | - |
| 2026-02-01 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | 1,88k | 0,00 | Derivative Exercise and Retained Stock | - | 28,14k | 7,17% |
| 2026-02-01 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | -1,51k | 1,57M | Derivative Exercise and Sale | 1,04k | 28,14k | - |
| 2026-02-01 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | 7,04k | 0,00 | Derivative Exercise and Retained Stock | - | 220,14k | 3,30% |
| 2026-02-01 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | -5,64k | 5,85M | Derivative Exercise and Sale | 1,04k | 220,14k | - |
| 2026-02-01 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | 2,20k | 0,00 | Derivative Exercise and Retained Stock | - | 31,41k | 7,53% |
| 2026-02-01 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | -1,91k | 1,98M | Derivative Exercise and Sale | 1,04k | 31,41k | - |
| 2026-02-01 | Mr. David A. RicksChairman & CEO | 17,64k | 0,00 | Derivative Exercise and Retained Stock | - | 751,81k | 2,40% |
| 2026-02-01 | Mr. David A. RicksChairman & CEO | -14,30k | 14,83M | Derivative Exercise and Sale | 1,04k | 751,81k | - |
| 2026-02-01 | Mr. Diogo RauExec. VP and Chief Information & Digital Officer | 2,08k | 0,00 | Derivative Exercise and Retained Stock | - | 21,80k | 10,54% |
| 2026-02-01 | Mr. Diogo RauExec. VP and Chief Information & Digital Officer | -1,67k | 1,74M | Derivative Exercise and Sale | 1,04k | 21,80k | - |
| 2026-02-01 | Mr. Patrik JonssonExec. VP & President of Lilly International | 2,18k | 0,00 | Derivative Exercise and Retained Stock | - | 56,44k | 4,01% |
| 2026-02-01 | Mr. Patrik JonssonExec. VP & President of Lilly International | -1,75k | 1,82M | Derivative Exercise and Sale | 1,04k | 56,44k | - |
| 2026-02-01 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | 1,98k | 0,00 | Derivative Exercise and Retained Stock | - | 42,58k | 4,88% |
| 2026-02-01 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | -1,59k | 1,65M | Derivative Exercise and Sale | 1,04k | 42,58k | - |
| 2026-02-01 | Ms. Anat HakimExec. VP, General Counsel & Secretary | 3,75k | 0,00 | Derivative Exercise and Retained Stock | - | 47,28k | 8,61% |
| 2026-02-01 | Ms. Anat HakimExec. VP, General Counsel & Secretary | -2,95k | 3,06M | Derivative Exercise and Sale | 1,04k | 47,28k | - |
| 2026-02-01 | Mr. Eric DozierExec. VP & CPO | 1,59k | 0,00 | Derivative Exercise and Retained Stock | - | 11,80k | 15,51% |
| 2026-02-01 | Mr. Eric DozierExec. VP & CPO | -1,27k | 1,32M | Derivative Exercise and Sale | 1,04k | 11,80k | - |
| 2026-01-07 | Lilly Endowment Inc.Société | -292,15k | 322,38M | Vente | 1,09k - 1,12k | 91,90M | -0,32% |
| 2026-01-05 | Lilly Endowment Inc.Société | -1,39k | 1,51M | Vente | 1,09k | 92,19M | -0,00% |
| 2025-12-29 | Lilly Endowment Inc.Société | -3,59k | 3,90M | Vente | 1,09k | 92,19M | -0,00% |
| 2025-12-23 | Lilly Endowment Inc.Société | -2,87k | 3,11M | Vente | 1,09k | 92,19M | -0,00% |
| 2025-11-25 | Lilly Endowment Inc.Société | -162,69k | 178,42M | Vente | 1,07k - 1,11k | 92,20M | -0,18% |
| 2025-11-24 | Lilly Endowment Inc.Société | -142,31k | 152,06M | Vente | 1,07k | 92,36M | -0,15% |
| 2025-11-21 | Lilly Endowment Inc.Société | -105,33k | 111,50M | Vente | 1,05k - 1,07k | 92,50M | -0,11% |
| 2025-11-20 | Lilly Endowment Inc.Société | -37,15k | 39,07M | Vente | 1,05k - 1,06k | 92,61M | -0,04% |
| 2025-11-19 | Lilly Endowment Inc.Société | -167,53k | 176,10M | Vente | 1,05k - 1,06k | 92,64M | -0,18% |
| 2025-11-18 | Lilly Endowment Inc.Société | -60,21k | 62,31M | Vente | 1,03k - 1,04k | 92,81M | -0,06% |
| 2025-11-17 | Lilly Endowment Inc.Société | -9,89k | 10,19M | Vente | 1,03k | 92,87M | -0,01% |
| 2025-11-14 | Lilly Endowment Inc.Société | -178,30k | 183,80M | Vente | 1,03k | 92,88M | -0,19% |
| 2025-11-13 | Lilly Endowment Inc.Société | -46,61k | 48,02M | Vente | 1,03k | 93,06M | -0,05% |
| 2025-11-13 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -1 000,00 | 1,01M | Automatic Disposition | 1,01k | 4,57k | -17,96% |
| 2025-11-12 | Lilly Endowment Inc.Société | -305,00k | 308,41M | Vente | 1,00k - 1,02k | 93,11M | -0,33% |
| 2025-11-10 | Lilly Endowment Inc.Société | -300,00k | 295,75M | Vente | 972,17 - 999,09 | 93,41M | -0,32% |
| 2025-11-10 | Mr. David A. RicksChairman & CEO | -24,75k | 0,00 | Other Disposition | - | 734,17k | -3,26% |
| 2025-11-10 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | -179,00 | 0,00 | Other Disposition | - | 213,10k | -0,08% |
| 2025-11-05 | Lilly Endowment Inc.Société | -219,47k | 205,57M | Vente | 911,01 - 954,95 | 93,71M | -0,23% |
| 2025-11-04 | Lilly Endowment Inc.Société | -526,00 | 479,04k | Vente | 910,72 | 93,93M | -0,00% |
| 2025-11-03 | Lilly Endowment Inc.Société | -300,00k | 266,65M | Vente | 877,40 - 900,79 | 93,93M | -0,32% |
| 2025-10-31 | Lilly Endowment Inc.Société | -301,34k | 260,17M | Vente | 862,63 - 869,47 | 94,23M | -0,32% |
| 2025-10-10 | Lilly Endowment Inc.Société | -3,66k | 3,16M | Vente | 862,34 - 863,37 | 94,53M | -0,00% |
| 2025-10-09 | Lilly Endowment Inc.Société | -10,60k | 9,04M | Vente | 848,63 - 857,26 | 94,54M | -0,01% |
| 2025-10-08 | Lilly Endowment Inc.Société | -101,42k | 86,23M | Vente | 848,46 - 856,00 | 94,55M | -0,11% |
| 2025-10-07 | Lilly Endowment Inc.Société | -26,80k | 22,72M | Vente | 848,01 | 94,65M | -0,03% |
| 2025-10-06 | Lilly Endowment Inc.Société | -161,18k | 137,04M | Vente | 848,30 - 855,71 | 94,68M | -0,17% |
| 2025-10-03 | Lilly Endowment Inc.Société | -192,40k | 161,22M | Vente | 821,42 - 847,60 | 94,84M | -0,20% |
| 2025-10-02 | Lilly Endowment Inc.Société | -112,60k | 92,50M | Vente | 821,09 - 833,92 | 95,03M | -0,12% |
| 2025-10-01 | Lilly Endowment Inc.Société | -351,02k | 284,65M | Vente | 765,75 - 833,15 | 95,14M | -0,37% |
| 2025-09-30 | Lilly Endowment Inc.Société | -113,69k | 86,79M | Vente | 763,10 - 766,12 | 95,49M | -0,12% |
| 2025-09-19 | Lilly Endowment Inc.Société | -23,67k | 18,06M | Vente | 763,05 - 764,47 | 95,61M | -0,02% |
| 2025-09-18 | Lilly Endowment Inc.Société | -106,63k | 81,53M | Vente | 763,29 - 767,07 | 95,63M | -0,11% |
| 2025-09-05 | Mr. Edgardo HernandezExec. VP & President of Manufacturing Operations | -17,00 | 0,00 | Other Disposition | - | 40,60k | -0,04% |
| 2025-08-27 | Mr. Kenneth L. CusterExec. VP & President of Lilly Cardiometabolic Health | 612,94 | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 2,17k | 39,29% |
| 2025-08-28 | Mr. Donald A. ZakrowskiSenior VP of Finance & CAO | -1 000,00 | 734,93k | Automatic Disposition | 734,93 | 5,57k | -15,23% |
| 2025-08-15 | Mr. Lucas E. MontarceExec. VP & CFO | 715,00 | 494,63k | Achat | 691,79 | 14,69k | 5,12% |
| 2025-08-13 | Mr. Ralph AlvarezIndependent Director | 758,00 | 500,47k | Achat | 660,25 | 758,00 | - |
| 2025-08-13 | Mr. Jacob S. Van NaardenExec. VP, President of Lilly Oncology & Head of Corporate Business Development | 1 000,00 | 647,36k | Achat | 647,36 | 29,21k | 3,55% |
| 2025-08-12 | Mr. David A. RicksChairman & CEO | 1,63k | 1,05M | Achat | 644,77 | 758,91k | 0,22% |
| 2025-08-12 | Dr. Daniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories | 1 000,00 | 634,41k | Achat | 634,41 | 213,28k | 0,47% |
| 2025-08-12 | Ms. Gabrielle SulzbergerIndependent Director | 117,00 | 75,02k | Achat | 641,18 | 2,70k | 4,52% |
| 2025-08-12 | Mr. Jon Erik FyrwaldIndependent Director | 1,57k | 1,01M | Achat | 642,00 - 642,59 | 1,68k | 1 326,27% |
| 2025-08-11 | Mr. Ilya YuffaExec. VP and President of Lilly USA & Global Customer Capabilities | -1,25k | 783,76k | Automatic Disposition | 627,01 | 26,26k | -4,54% |
| 2025-08-08 | Mr. Jamere JacksonIndependent Director | 200,00 | 127,91k | Achat | 639,56 | 200,00 | - |
| 2025-08-01 | Ms. Melissa S. SeymourExec. VP of Global Quality | 525,08 | 0,00 | Derivative Exercise and Retained Stock | - | 525,00 | - |
| 2025-08-01 | Ms. Melissa S. SeymourExec. VP of Global Quality | -426,92 | 315,95k | Derivative Exercise and Sale | 740,07 | 525,00 | - |
| 2025-07-24 | Lilly Endowment Inc.Société | -280,00k | 225,42M | Vente | 803,48 - 808,34 | 95,74M | -0,29% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
